造影剤の市場規模、シェア、成長分析：タイプ別、画像診断法別、投与経路別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

造影剤2023年の市場規模は54億米ドルで、2024年の55億6,000万米ドルから2032年には70億5,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは3.0％で成長する見通しです。

複雑な併存疾患や慢性疾患の増加により、超音波、X線、MRI、CTスキャンなどの画像診断が顕著に増加しています。2022年9月、米国FDAは高い相対性とガドリニウム投与量の低減を特徴とする新規MRI造影剤であるガドピクレノールを承認し、重要なマイルストーンが達成されました。この進歩により、成人および2歳以上の小児を対象に、患者の安全性を高めながら撮影精度を向上させることができます。ガドピクレノールの製剤は、従来の造影剤に関連するリスクを軽減する必要性の高まりに対応するものであり、画像診断技術の進化における重要な前進を示すとともに、幅広いヘルスケアの要求に応えるものです。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

造影剤市場規模：タイプ別

• 市場概要
• ヨウ素化造影剤
• ガドリニウムベース造影剤
• バリウムベース造影剤
• マイクロバブル造影剤
• その他

造影剤市場規模：画像診断法別

• 市場概要
• X線/CT
• MRI
• 超音波
• その他

造影剤市場規模：投与経路別

• 市場概要
• 血管内
• 経口/直腸
• その他

造影剤市場規模：用途別

• 市場概要
• 心臓血管
• 神経疾患
• がん
• 胃腸障害
• 筋骨格障害
• その他

造影剤市場規模：エンドユーザー別

• 市場概要
• 病院
• 画像診断センター
• 外来手術センター
• その他

造影剤市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Bayer AG（Germany）
• Bracco Imaging SpA（Italy）
• GE Healthcare（US）
• Guerbet（France）
• Lantheus Medical Imaging, Inc.（US）
• NanoPET Pharma GmbH（Germany）
• Fujifilm Corporation（Japan）
• Beijing Beilu Pharmaceutical Co. Ltd.（China）
• Taejoon Pharm Co. Ltd.（South Korea）
• Jubilant Life Sciences Ltd.（India）
• Siemens Healthineers（Germany）
• Philips Healthcare（Netherlands）
• Cardinal Health（US）
• McDermott International（US）
• Medtronic（Ireland）
• Terumo Corporation（Japan）
• Abbott Laboratories（US）
• Baxter International（US）
• Fresenius Medical Care AG & Co. KGaA（Germany）
• Novartis AG（Switzerland）

結論と提言

Contrast Agents Market size was valued at USD 5.4 billion in 2023 and is poised to grow from USD 5.56 billion in 2024 to USD 7.05 billion by 2032, growing at a CAGR of 3.0% during the forecast period (2025-2032).

The increasing prevalence of complex comorbidities and chronic conditions is driving a notable rise in diagnostic imaging procedures, including ultrasounds, X-rays, MRIs, and CT scans. A key milestone was achieved in September 2022 when the U.S. FDA approved Gadopiclenol, a novel MRI contrast agent characterized by high relativity and a reduced gadolinium dosage. This advancement enhances imaging precision while ensuring heightened patient safety for both adults and children aged two years and above. Gadopiclenol's formulation addresses the growing need to mitigate risks linked to traditional contrast agents, indicating a significant step forward in the evolution of diagnostic imaging technology and catering to a wide array of healthcare requirements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Contrast Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Contrast Agents Market Segments Analysis

Global Contrast Agents Market is segmented by Type, Imaging Modality, Route of Administration, Application, End User and region. Based on Type, the market is segmented into Iodinated Contrast Agents, Gadolinium-Based Contrast Agents, Barium-Based Contrast Agents, Microbubble Contrast Agents and Others. Based on Imaging Modality, the market is segmented into X-Ray/CT, MRI, Ultrasound and Others. Based on Route of Administration, the market is segmented into Intravascular, Oral/Rectal and Others. Based on Application, the market is segmented into Cardiovascular, Neurological Disorders, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders and Others. Based on End User, the market is segmented into Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Contrast Agents Market

The growing acceptance of image-guided surgeries (IGS) represents a pivotal trend within the medical field. As these procedures gain popularity, they play a crucial role in both diagnosing and treating a wide range of medical conditions. This rising demand for accurate, real-time imaging improvements during surgical procedures highlights the need for innovative techniques in data acquisition, processing, and display. Additionally, there is an increasing emphasis on understanding imaging processes and their clinical applications. This landscape creates a significant opportunity for advancements in contrast agents that enhance visualization and precision in image-guided surgical practices.

Restraints in the Contrast Agents Market

The Contrast Agents market faces certain impediments, despite advancements in medical technology and the development of improved contrast agent formulations. A portion of patients still experiences side effects or allergic reactions related to these agents. Although these adverse reactions are relatively infrequent, they can vary in severity, from mild discomfort to critical conditions that require urgent medical intervention. Common symptoms include skin reactions, nausea, and shortness of breath; in rare instances, they can escalate to more serious concerns, such as anaphylaxis. These potential health risks place constraints on the widespread adoption of contrast agents in medical procedures.

Market Trends of the Contrast Agents Market

The Contrast Agents market is poised for significant growth, driven by the increasing prevalence of multiple chronic conditions among the aging population. As nearly 80% of individuals aged 65 and older suffer from at least one chronic ailment, the demand for advanced imaging techniques, facilitated by contrast agents, is surging. This demographic shift, projected to see 77 million seniors in the U.S. by 2034, highlights the urgent need for enhanced diagnostics to address the complexities of managing multiple comorbidities. Consequently, the demand for innovative contrast agents is expected to rise sharply, creating lucrative opportunities for key players in the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Contrast Agents Market Size by Type & CAGR (2025-2032)

• Market Overview
• Iodinated Contrast Agents
• Gadolinium-Based Contrast Agents
• Barium-Based Contrast Agents
• Microbubble Contrast Agents
• Others

Global Contrast Agents Market Size by Imaging Modality & CAGR (2025-2032)

• Market Overview
• X-Ray/CT
• MRI
• Ultrasound
• Others

Global Contrast Agents Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravascular
• Oral/Rectal
• Others

Global Contrast Agents Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cardiovascular
• Neurological Disorders
• Cancer
• Gastrointestinal Disorders
• Musculoskeletal Disorders
• Others

Global Contrast Agents Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers
• Others

Global Contrast Agents Market Size & CAGR (2025-2032)

• North America (Type, Imaging Modality, Route of Administration, Application, End User)
  • US
  • Canada
• Europe (Type, Imaging Modality, Route of Administration, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Imaging Modality, Route of Administration, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Imaging Modality, Route of Administration, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Imaging Modality, Route of Administration, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging SpA (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoPET Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Beilu Pharmaceutical Co. Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taejoon Pharm Co. Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Life Sciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• McDermott International (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations